We have identified satraplatin as having a significant effect in haemato-oncology indications and are developing it as a precision platinum for orphan lymphomas.
We are scaling up the identification and development of clinical compounds using proprietary oncologist know-how by amplifying the process with AI and data mining to systematically pursue high-yield candidates for cancer indications of large unmet medical need.
Based on our positive experience with two compounds,
the Onco-indication engine will be scaled up.
We are oncologists, scientists and entrepreneurs, and we believe in the power of innovation to unlock new therapies for patients in need of therapeutic options.
By adapting drugs for new oncology indications, Dayton Therapeutics maximises the utility of drug developments and provides a risk-mitigated pipeline of future launches.